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Murine sclerodermatous graft-versus-host disease (Scl
GVHD), produced by transplanting B10.D2 bone mar-
row and spleen cells to lethally irradiated BALB/cJ
mice, is a model for human scleroderma. Mice with
Scl GVHD have skin thickening, lung ¢brosis, cuta-
neous mononuclear cell in¢ltration, and upregulation
of cutaneous transforming growth factor b1 (TGF-b1)
and type I collagen mRNAs by day 21 after bone mar-
row transplantation. Elevated TGF-b1 appears to be the
critical cytokine driving ¢brosis in Scl GVHD, which
can be prevented with antibodies to TGF-b adminis-
tered early in disease. Here we demonstrate that we
can also prevent skin thickening in mice with Scl GVHD
with a naturally occurring antagonist to TGF-b1, human
latency-associated peptide (LAP). By quantitative real-
time PCR analysis and immunostaining, LAP treat-
ment also abrogates the upregulation of cutaneous
TGF-b1 and connective tissue growth factor mRNAs
and type I collagen synthesis in Scl GVHD. In contrast
to anti-TGF-b antibodies, LAP at 4 ng total per mouse
has no signi¢cant suppressive e¡ect on cutaneous in£ux
of T cells and monocytes or immune cell activation.
LAP may be a potential new therapy in scleroderma
and other TGF-b-driven ¢brosing disease that targets
TGF-b more speci¢cally, without a¡ecting systemic
critical roles of TGF-b on immune cell function. Key
words: LAP/TGF-b/macrophages. J Invest Dermatol 121:
713 ^719, 2003
S
cleroderma is a chronic progressive multisystem disease,
for which there is no e¡ective treatment to date. This
autoimmune disease is characterized by skin thickening
and visceral ¢brosis that may a¡ect lungs, gastrointest-
inal tract, heart, and kidneys in the rapidly progressive
systemic form of scleroderma (systemic sclerosis) (Mitchell et al,
1997; Steen, 1998). Murine sclerodermatous graft-versus-host dis-
ease (Scl GVHD), produced by transplanting B10.D2 (H-2d) bone
marrow and spleen cells across minor histocompatibility loci into
lethally irradiated BALB/cJ (H-2d) recipients, has many clinical
and histologic similarities to scleroderma. In these experiments,
syngeneic (BALB/c into BALB/c) transplanted animals are always
the controls. The Scl GVHD model recapitulates important
features of human scleroderma in which skin thickening, lung
¢brosis, and in¢ltrating cutaneous mononuclear cells (predomi-
nantly monocytes and T cells) are seen. In this study we have fo-
cused on skin. Skin thickening is stable and persists to at least day
75 after bone marrow transplantation (BMT). Increased cuta-
neous transforming growth factor b1 (TGF-b1) and collagen ex-
pression are prominent by day 21 after BMT (McCormick et al,
1999). Unlike classic GVHD, Scl GVHD shows mainly ¢brosis,
with minimal cytotoxic injury to epithelia (Gilliam and Murphy,
1997; Zhang and Gilliam, 2002; Gilliam, 2003). This form of
GVHD may model early explosive scleroderma that progresses
over months rather than years.
Activated TGF-b1 is a potent ¢brogenic cytokine, known to
induce collagen synthesis by ¢broblasts in vitro and in vivo. It
may play a central role in development of various ¢brosing dis-
eases including scleroderma (Mitchell et al, 1997). TGF-b1 appears
to be the critical isoform in murine Scl GVHD and in a murine
bleomycin model for scleroderma (Yamamoto et al, 1996b; Zhang
et al, 2002). TGF-b is secreted as a latent complex (LTGF-b)
consisting of a 25-kDa dimeric protein bound to latency-
associated peptide (LAP), the 40-kDa N-terminal peptide of precur-
sor TGF-b. LAP is cleaved from the precursor TGF-b protein,
dimerizes, and noncovalently associates with mature dimerized
TGF-b (Roberts, 1998). Disruption of the noncovalent interac-
tions between LAP and TGF-b, either by conformational changes
or by complete dissociation of LAP (induced by extremes of pH,
heat, serine protease plasmin, thrombospondin-1), results in acti-
vation of TGF-b (Oklu and Hesketh, 2000). EachTGF-b isoform
(TGF-b1, -b2, -b3) has its corresponding LAP, and the di¡erent
isoforms of TGF-b have di¡erent functions in embryonic devel-
opment, wound healing, and tissue ¢brosis. Human LAP1 pep-
tide is 86% homologous to mouse LAP1, and recombinant
human TGF-b1 LAP inhibits human and mouse TGF-b1 in vitro
and in vivo (Gentry and Nash, 1990; Miller et al, 1992; Bottinger
et al, 1996). Activated TGF-b1 orchestrates with other cytokines
and chemokines in chemoattraction of immune cells to in£am-
matory sites and in modulation of collagen synthesis and/or
deposition via the Smad signaling pathway (Lawrence, 1996).
Blocking antibodies (Abs) to TGF-b e¡ectively prevent skin
thickness and lung ¢brosis in the murine Scl GVHD model
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(McCormick et al, 1999) and in murine bleomycin-induced skin
¢brosis (Yamamoto et al, 1999a) and scarring in animal and hu-
man wounds (Shah et al, 1992), and they inhibit induced glomer-
ulonephritis in a rat model (Border et al, 1990). Intraperitoneal
administration of recombinant human LAP e¡ectively blocks
TGF-b1 inhibition of hepatocyte proliferation after partial liver
resection in TGF-b1 transgenic mice (Bottinger et al, 1996; Lut-
tenberger et al, 2000).
Connective tissue growth factor (CTGF) is thought to be a
downstream mediator of TGF-b function that also plays an im-
portant role in development and maintenance of synthesis and
deposition of extracellular matrix components (¢bronectin, col-
lagen I and IV) by ¢broblasts and renal mesangial cells (Leask
et al, 2002). Overexpression of CTGF is found in several progres-
sive ¢brotic diseases such as renal sclerosis, liver cirrhosis, and
scleroderma (Igarashi et al, 1996; Ito et al, 1998; Abou-Shady et al,
2000; Sato et al, 2000; Leask et al, 2002). CTGF is a TGF-b-indu-
cible immediate early gene in ¢broblasts. Its induction byTGF-b
is mainly at the transcriptional level via a uniqueTGF-b response
element and a Smad-binding sequence within the CTGF promo-
ter (Grotendorst et al, 1996).
We asked whether LAP would prevent skin ¢brosis in Scl
GVHD by speci¢cally inactivating mature functional TGF-b1
and CTGF. We found that like anti-TGF-b Abs, LAP can also
prevent skin thickening in Scl GVHD mice. In contrast to anti-
TGF-b Abs, which prevent cutaneous T-cell and monocyte/
macrophage in£ux into skin, LAP has no e¡ect on immune cell
activation or migration into skin, suggesting a more speci¢c tar-
geting of TGF-b for which mRNA levels are also reduced.We
found that cutaneous CTGF mRNA levels were also reduced
after in vivo LAP treatment. Use of this small molecule, available
as a recombinant human LAP peptide, would allow treatment of
¢brosing disease without the systemic e¡ects of blocking multi-
ple other pathways in systemic TGF-b function. To our know-
ledge this is the ¢rst report using LAP to treat ¢brosing Scl
GVHD in vivo.
MATERIALS AND METHODS
BMT Seven- to 8-wk-old female B10.D2 (nSnJ, H-2d, m1s2a, m1s3a) and
BALB/cJ (H-2d m1s2a, m1s3a) (Jackson Laboratory, Bar Harbor, ME) mice
were utilized for BMT to produce Scl GVHD (Korngold and Sprent, 1978;
Ja¡ee and Claman, 1983; McCormick et al, 1999; Gilliam, 2003) per
institutional approval. Recipient mice (BALB/c) were lethally irradiated
with 700 cGy from a Gammacel 137Cs source. Approximately 6 h later,
they were injected by tail vein with donor bone marrow (1106 per
mouse, as a source of hematopoietic stem cells) and spleen cells (2106
per mouse, as a source of mature T cells) suspended in RPMI 1640 (Bio-
Whittaker, Frederick, MD) with 20 U per mL heparin (Fisher Scienti¢c,
Pittsburgh, PA) (Korngold and Sprent, 1978). Control BALB/c recipient
mice received BALB/c spleen and bone marrow cells (syngeneic BMT
controls). Experimental BALB/c recipient mice received B10.D2 spleen
and bone marrow cells. Mice that did not engraft died within 7 to 10 days.
Transplanted animals were maintained in sterile Micro-Isolator cages (Labo-
ratory Products, Seaford, DE) and supplied with autoclaved food and acidi¢ed
water.
Recombinant human LAP treatment Mice were administered two
doses of 2 ng of recombinant human LAP (TGF-b1) (R & D Systems,
Minneapolis, MN) suspended in 100 mL of phosphate-bu¡ered saline
containing 0.1% bovine serum albumin by tail vein injection on days 1
and 6 after BMT. The dose was selected based on in vivo studies in other
systems (Bottinger et al, 1996). These experiments were performed three
times, each time with consistent results.
Collection of tissue Three to ¢ve mice per experimental condition, per
group (Scl GVHD or control BMT), were euthanized via cervical
dislocation on days 7, 14, and 21 after BMT. Days 14 and 21 were chosen
because they are the earliest time points at which there are relia-
ble changes in skin thickening and in£ammation (McCormick et al,
1999). Back skin was depilated and harvested for RNA extraction, £ow
cytometry, immunostaining (frozen on dry ice and stored at 801C), and
routine histologic staining.Tongue and lung were also collected for routine
histology to evaluate for the development of GVHD.
Histologic and morphometric analysis Bu¡ered formalin-¢xed
(10%; Surgipath Medical Industries, Inc., Richmond, IL), para⁄n-embed-
ded sections of tissue were stained by hematoxylin and eosin. For morpho-
metric analysis, histologic sections of back skin were scanned with a CCD
camera (Optronics, Goleta, CA) using an Axiophot photomicroscope
system (C. Zeiss, Oberkochen, Germany), stored as ti¡ ¢les, and subjected
to image analysis (Optimas 6.1, Bothell, WA). Dermal thickening from
bottom of epidermis to fat was evaluated for each animal as previously
described (McCormick et al, 1999; Gilliam 2003) and reported as ‘‘skin
thickness.’’
Antibodies
Immunostaining Primary Abs and corresponding isotype control Abs
were as follows: anti-CD11b (anti-Mac-1, monoclonal Ab (mAb) M1/70,
rat IgG2b, PharMingen, San Diego, CA) was used to identify monocyte/
macrophages. Anti-CD3 (mAb 17A2, rat IgG2b, PharMingen) was used to
identifyT cells. Mouse collagen I (rabbit anti-mouse polyclonal antiserum,
Chemicon,Temecula, CA) was used to identify type I collagen protein in
tissue. Goat anti-rat IgG^biotin or goat anti-rabbit IgG^biotin (Vector La-
boratories, Burlingame, CA) followed by peroxidase-labeled streptavidin
(Kirkegaard and Perry Laboratories, Gaithersburg, MD) and diaminoben-
zidine (Kirkegaard and Perry Laboratories) was used for detection. Diami-
nobenzidine orange enhancer (Kirkegaard and Perry Laboratories) was
used for type I collagen staining. Isotype control Abs were rat anti-IgG2b
(R35-38, PharMingen) and normal rabbit IgG (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA).
Flow cytometry Indirect single-color stains were performed for scavenger
receptor macrophage receptor with collagenous structure (mature mono-
cyte/macrophages, mAb ED31, rat IgG1, Serotec) using F(ab0)2 anti-rat
IgG^FITC (Jackson ImmunoResearch Laboratories, Inc.,West Grove, PA)
to detect bound Ab. Direct single stains were performed with Abs to
CD45, CD3, and CD11b. Direct two-color stains were performed in the
following groupings: anti-CD45 (leukocytes from hematopoietic origin,
mAb LY-5, rat IgG2b^FITC) and anti-I-Ad (mAb AMS-32.1, mouse
IgG2b^PE), anti-CD3 (T cells, mAb 17A2, rat IgG2b^PE) and anti-I-Ad,
and anti-CD11b (anti-Mac-1, mAb M1/70, rat IgG2b^PE) and anti-I-Ad.
The corresponding isotype controls were used for instrument setup. Ex-
cept as noted, all speci¢c primary, secondary, and isotype Abs for two-col-
or £ow cytometry were from PharMingen.
Preparation of skin cell suspensions for £ow cytometry As
described previously (Hammerberg et al, 1996; McCormick et al,
1999; Gilliam, 2003), small pieces of depilated skin were digested in
RPMI containing 10 mM HEPES (Irvine Scienti¢c, Santa Ana, CA),
0.01% DNase (Sigma), 0.27% collagenase (Sigma), and 1000 units of
hyaluronidase (Sigma) at 371C for 2 h. The digested skin was ¢ltered
through 100-mm nylon mesh to generate a single-cell suspension
of dermal cells, containing resident cells (keratinocytes, ¢broblasts,
endothelial cells, perivascular cells such as mast cells) and in¢ltrating cells
(lymphocytes, NK cells, and monocytes). Approximately 4106 cells were
typically obtained from a 12-cm2 piece of skin for control mice and
8106 cells for mice with Scl GVHD at day 21. Before speci¢c Ab
staining, all isolated skin cells were blocked with puri¢ed murine IgG (1
mg per 106 cells, Sigma) for 5 min on ice. Speci¢c and isotype-matched
Abs were then directly applied (1 mg per 106 cells). Before ¢xation with
1% paraformaldehyde in phosphate-bu¡ered saline, all samples were
washed twice in phosphate-bu¡ered saline supplemented with 1% bovine
serum albumin, 1% fetal calf serum, and 0.05% sodium azide. Samples
were acquired on a FACScan (Becton-Dickinson, Franklin Lakes, NJ) and
the data analyzed using Cell Quest software.
Immunohistochemistry Frozen skin was embedded in OCT (Miles,
Elkhart, IN), sectioned by cryostat (Leica CM1800, Nussloch, Germany),
and ¢xed in cold acetone for immunostaining using ABC methods
(Gilliam et al, 1998). Staining was performed at least three times on each
specimen. In all immunostaining experiments, isotype control Abs are
always used on tissue on the same slide to compare with speci¢c Ab
staining.
RNA puri¢cation Dissected depilated back skin from euthanized
animals at each time point was snap-frozen in liquid nitrogen and stored
at ^801C for RNA isolation. RNA was extracted using Trizol reagent
(Gibco BRL, Gaithersburg, MD) and stored at ^801C as described
previously (McCormick et al, 1999).
Quantitative real-time PCR analysis Primers were designed using
primer design program (Primer Express 1.5) based on murine sequences
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obtained from the Genbank database (Table I). PCRs contained 2 mL
(equating 100 ng of total RNA) of reverse transcription reaction pro-
ducts; speci¢c oligonucleotide primers for TGF-b1, CTGF, or GAPDH,
10PCR bu¡er, 0.8 mM dNTP mix, 1.25 units of SureStart Taq DNA
polymerase, 2 mM MgCl2, 300 nM reference dye, and SYBR Green dye
(brilliant quantitative PCR core reagent kit, Stratagene, La Jolla, CA) in a
volume of 25 mL. Reactions were held at 501C for 2 min and then heated
to 951C for 10 min, followed by four cycles of ampli¢cation: 15 s at 941C
and 1 min at 601C using the ABI Prism 7700 sequence detection system
(Applied Biosystems, Foster City, CA). Reactions were also performed
in the absence of reverse transcriptase and were always negative. SYBR
Green £uorescence was detected and plotted for each cycle during the
601C extension phase using Sequence Detection Systems 1.7 software.
Threshold cycles (CT values) and target gene expression were calculated
using Q-Gene software.
Data analysis and statistics All of the data are expressed as
means7SEM, and an unpaired t test (two-tailed) was used for statistical
signi¢cance to determine di¡erences among means of treatment,
experimental, and control groups. Di¡erences with po0.05 were con-
sidered signi¢cant.
RESULTS
LAP treatment prevents skin thickening in Scl
GVHD Because upregulated TGF-b1 appears to play a critical
role in the development of scleroderma and Scl GVHD, and
because recombinant human LAP inhibits murine TGF-b in vitro
and in vivo, we asked whether inactivation of mature TGF-b by
LAP, the naturally occurring peptide inhibitor of TGF-b, could
prevent skin ¢brosis in early Scl GVHD. Human LAP (R & D
Systems, 2 ng per mouse per time point) was administered to
animals at days 1 and 6 after BMT followed by euthanization on
day 21 when all parameters of Scl GVHD are demonstrable,
including skin thickening and upregulated TGF-b1 and pro(a1)
collagen I mRNAs (McCormick et al, 1999; Gilliam, 2003). This
dose is also within the range of those used for inhibition of TGF-
b in other mouse models (Bottinger et al, 1996). LAP treatment
e¡ectively prevented skin thickening in murine Scl GVHD (Fig 1)
but did not alter successful BMT, as evidenced by colonization of
the spleen in both control and experimental mice (data not
shown) and by survival of LAP-treated animals. LAP treatment
of syngeneic BMT control animals had no e¡ect on skin
thickness (data not shown). Therefore, LAP prevents the
cutaneous ¢brosis in early Scl GVHD, presumably by associating
with active TGF-b1 to form latent complexes. Both sets of
experimental animals have diminished fat layers compared to
controls, probably owing to mild early systemic GVHD e¡ects.
These e¡ects are common in all our experiments; at later time
points (by day 49 after BMT), the thickness of fat layers is
restored in all transplanted animals.
LAP treatment inhibits cutaneous TGF-b1 mRNA
upregulation in Scl GVHD Because we hypothesized that
skin ¢brosis is driven by TGF-b1 in early murine Scl GVHD,
quantitative real-time PCR for TGF-b1 was performed on total
skin RNA from LAP-treated experimental animals. By day 21
after BMT, cutaneous TGF-b1 mRNA in skin of experimental
animals receiving recombinant human LAP was reduced and
was comparable to controls, whereas untreated experimental
animals with Scl GVHD had elevated TGF-b1 mRNA in skin
(4.7-fold increase compared with controls) (Fig 2A). These
results suggest a feedback mechanism of LAP in TGF-b mRNA
synthesis, a novel ¢nding.
LAP treatment inhibits cutaneous CTGF mRNA
upregulation in Scl GVHD CTGF is a downstream mediator
of TGF-b function that is upregulated in human scleroderma
(Sato et al, 2000; Leask et al, 2002). Recombinant CTGF can
induce ¢bronectin and collagen I and IV protein synthesis when
added to renal mesangial cells in vitro (Murphy et al, 1999). By
21 days after BMT, cutaneous CTGF mRNA expression is
upregulated in Scl GVHD mice compared to syngeneic controls
(2.8-fold increase analyzed by quantitative real-time PCR),
Table I. Real-time quantitative PCR primers
Primer sequences (50^30) Product size (bp) Genbank reference
GAPDH Sense: AACGACCCCTTCATTGAC 191 M32599
Antisense: TCCACGACATACTCAGCAC
TGF-b1 Sense: GACTCTCCACCTGCAAGACCA 100 NM011577
Antisense: GGGACTGGCGAGCCTTAGTT
CTGF Sense: GGAAGACACATTTGGCCCAG 100 NM010217
Antisense: AGATGCCCATTCCACAGGTC
Figure1. Skin thickening in Scl GVHD is inhibited by LAP. Four
nanograms total of human recombinant LAP was administered to mice at
days 1 and 6 after BMT in three separate experiments. The top panels show
representative micrographs of skin histology at day 21 after BMT. LAP-
treated animals have no skin thickening, compared to untreated Scl GVHD
animals. Untreated Scl GVHD skin is thicker than controls and shows in-
creased in£ammatory cell in¢ltrates. Although not apparent in these low-
power views (10 ), in£ammatory cells are still present in skin of LAP-
treated Scl GVHD animals. In the graph in the bottom panel, bars represent
the means and SD of the skin thickness taken from (n) animals in a com-
bined experiment (of two) (p¼ 0.0003 using a unpaired t test to compare
Scl GVHD animal back skin thickness to syngeneic BMT control animal
back skin thickness; p¼ 0.0006 when Scl GVHD and LAP-treated Scl
GVHD mice are compared using a unpaired t test). Skin thickness was de-
termined by image analysis of hematoxylin and eosin-stained tissue sec-
tions using Optimas software as described under Materials and Methods.
Bar, 200 mm.
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whereas in the skin of LAP-treated mice, CTGF expression is
reduced almost to control levels (Fig 2B), suggesting that CTGF
expression may be mediated by TGF-b-dependent pathways in
our model.
LAP treatment inhibits type I collagen synthesis in Scl
GVHD We next asked whether inhibition of skin thickening
in Scl GVHD by LAP is due to decreased collagen synthesis.
Immunostaining was performed to detect cutaneous type I
collagen protein synthesis. By day 21 after BMT, total cutaneous
type I collagen protein that is increased in untreated Scl GVHD is
dramatically decreased by immunostaining in experimental
animals receiving LAP (Fig 3A).
LAP does not alter cutaneous immune cell in£ux in
Scl GVHD In contrast to anti-TGF-b Ab treatment (Zhang
et al, 2002), which abrogates immune cell in£ux into skin
and cutaneous immune activation and skin thickening, LAP
treatment prevents skin thickening without a¡ecting cutaneous
immune cell in¢ltration by immunostaining and £ow
cytometric analysis. We found that the numbers of cutaneous
CD45þ cells, CD3þT cells, and CD11bþ macrophages in
LAP-treated and untreated experimental groups are the same
(Figs 3B^D, 4A). Therefore, LAP appears to act further
downstream from anti-TGF-b Abs, which may a¡ect chemo-
taxis of immune cells.
Activation markers of cutaneous immune cells on LAP-
treated mice in Scl GVHD Upregulation of surface MHC
class II (I-Ad) expression is a marker of activation on T cells
and monocyte/macrophages. We used a speci¢c Ab to I-Ad that
recognizes immune cells of both donor and recipient mice to
evaluate for activation by immunostaining and by £ow
cytometric analysis. Similar to our previous ¢ndings, I-Ad levels
are elevated on CD45þ cells in mice with Scl GVHD, but not in
controls by day 14. I-Ad remains elevated on day 21 (Fig 4B)
(Zhang et al, 2002). The I-A molecule upregulation is attributed
to both macrophages and T cells, as indicated by an increase in
mean £uorescence intensity after gating on both CD11b- and
Figure 2. TGF-b1 (A) and CTGF (B) mRNAs are decreased at day
21 in LAP-treated experimental animals by quantitative real-time
PCR analysis on total skin RNA. TheY axis is a calculated mean nor-
malized expression of target gene to GAPDH that re£ects the abundance of
target gene compared to a reference gene, GAPDH.TGF-b1 appears to be a
low-abundance mRNA (relatively low copies in skin), whereas CTGF
mRNA appears to be high abundance (with higher copy numbers), re-
£ected in the larger scale for CTGF. In the graph, bars represent the mean
and SD of the normalized expression of TGF-b1 and CTGF from (n) ani-
mals in a combined experiment (of two of three total), n¼ 3^5 in each
group (unpaired t test is used; p¼ 0.007 in TGF-b1 and p¼ 0.01 in CTGF
when Scl GVHD and LAP-treated Scl GVHD mice are compared).
Figure 3. LAP administered on days 1 and 6 after BMT e¡ectively
prevents cutaneous type I collagen overproduction without a¡ect-
ing immune cell in£ux into skin or cutaneous immune cell activa-
tion in Scl GVHD.We show immunostaining results on acetone-¢xed
frozen skin sections from syngeneic BMT control, Scl GVHD, and LAP-
treated Scl GVHD mice on day 21 after BMT when skin thickening in
Scl GVHD animals is abrogated. (A) Stained with type I collagen antiser-
um; (B) anti-CD45 Ab; (C) anti-CD3 Ab; (D) anti-CD11b Ab; (E) anti-I-
Ad Ab. Staining with isotype control Abs (on the same slide with speci¢c
Ab) is always negative (not shown). Micrographs show immunostaining
results from a representative animal per group (n¼ 3^5), all at 40 mag-
ni¢cation. At this magni¢cation in these micrographs, the di¡erence in
skin thickness between Scl GVHD and controls are not apparent. The ap-
parent increased staining at the base of the third panel (Scl GVHDþLAP) in
A is edge e¡ect. Bar, 50 mm.
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CD3-expressing cells. We have shown previously (Zhang et al,
2002) that NK cells that are also CD11bþ are a very small
percent of total CD45þ cells in skin. In contrast to our results
using polyclonal anti-TGF-b Ab to inhibit skin ¢brosis (Zhang
et al, 2002), administration of LAP did not decrease the level of
I-Ad in mice with Scl GVHD by immunostaining (Fig 3E) and
£ow cytometric analysis (Fig 4B). The results of LAP adminis-
tration between experimental groups are statistically insigni¢cant.
Therefore, by several di¡erent parameters (in£ux of immune cells
into skin, surface activation markers), LAP inhibition of skin
¢brosis in Scl GVHD appears to act mainly on the cytokine
TGF-b1, inhibiting its e¡ects on ¢broblast collagen synthesis, and
on synthesis of cutaneous TGF-b mRNA, but not on chemotaxis,
homing, or activation of cutaneous immune cells.
DISCUSSION
Skin ¢brosis and thickening in scleroderma and in Scl GVHD are
incompletely understood and involve multiple di¡erent types of
immune cells and a complex network of chemokines and cyto-
kines. We hypothesize that during early phases of murine Scl
GVHD, activated T cells and macrophages in skin secrete TGF-
b1. Secreted TGF-b1 plus preformed LTGF-b1 bound to matrix
are activated by a unknown mechanism in vivo, in which LAP
peptide dissociates fromTGF-b dimers. TGF-b1 is both cytokine
and chemokine, and soTGF-b production by cutaneous immune
cells leads to recruitment of more macrophages and T cells into
skin.We showed that TGF-b1-producing monocyte/macrophages
expressing markers of activation and antigen presentation are the
predominant cutaneous cells in Scl GVHD (Zhang et al, 2002).
These macrophages may present modi¢ed self-antigens to in¢l-
trating T cells, which then further stimulate TGF-b1 synthesis.
Upregulated TGF-b1 then promotes collagen synthesis and ECM
deposition and causes skin thickening, regardless of its source
(Fig 5 model).
In previous studies we have shown upregulation of cutaneous
TGF-b1 and collagen mRNA synthesis, skin thickening, and
lung ¢brosis accompany prominent immune cell in£ux into skin
by day 21 after BMT in murine Scl GVHD (McCormick et al,
1999). Rabbit polyclonal Abs to TGF-b inhibit all these para-
meters of ¢brosis.We show here that human LAP, the naturally
occurring peptide proregion of precursor TGF-b1 administered
early in disease, also prevents skin thickening. Like Abs to TGF-
b, LAP blocks the upregulation of TGF-b1mRNA and collagen
protein in animals with Scl GVHD compared to syngeneic BMT
controls. LAP also prevents upregulation of CTGF. In contrast to
anti-TGF-b Abs, LAP does not abrogate immune cell in£ux into
skin, nor does it a¡ect the activation status of these in¢ltrating
cells in our model. Our data provide a foundation for interven-
tions in ¢brosing disease such as Scl GVHD and early scleroder-
ma by the functional inactivation of active ¢brogenic TGF-b1 in
vivowith LAP.This may be a more speci¢c and targeted interven-
tion than blocking Abs, which can interfere with other path-
ways such as chemokine synthesis and immunoregulation of other
cytokine pathways. In addition, mAb administration is often
complicated by development of an immune response to Abs to
proteins from another species. The LAP molecule for TGF-b1
has a high homology across species and is less likely to induce
an immune response.
Latency and activation: TGF-b in ¢brosing diseases TGF-b
is a pleiotropic cytokine that is critical for control of extracellular
matrix production, modulation of in£ammatory cell function,
and epithelial growth inhibition and di¡erentiation. Elevated
TGF-b in the circulation and in diseased organs has been
implicated in the pathogenesis of ¢brosis (Jimenez et al, 1996).
The mammalian TGF-b family mainly consists of three closely
related isoforms (TGF-b1, -b2, and -b3). TGF-b isoforms have
multiple di¡erent e¡ects in vivo, including stimulation of
collagen synthesis, remodeling of tissue in embryogenesis,
chemoattraction, autoinduction of TGF-b and induction of
CTGF, modulation of immune cells, inhibition of epithelial
proliferation, and di¡erentiation of hematopoietic precursors to
dendritic cells (Lawrence, 1996; Letterio and Roberts, 1998;
Massague, 2000). TGF-b1 is a known stimulus for ¢broblast
collagen synthesis (Roberts et al, 1986; Varga et al, 1987; Smith
and LeRoy, 1990). TGF-b2 and -b3 may also be involved in
various ¢brosing diseases (Kulozik et al, 1990; O’Kane and
Ferguson, 1997). Nevertheless, mature activated TGF-b1 appears
to be the critical ¢brogenic cytokine during development of
early ¢brosing disease in murine models of scleroderma, leading
to progressive accumulation of extracellular matrix (Yamamoto
et al, 1999b; Zhang et al, 2002). TGF-bs are secreted as latent
forms (LTGF-b); they must be activated by release of LAP
(Fig 5) before they are functional. The exact mechanism of LTGF-
b activation in our model is not known. In vitro and in vivo work
in other systems suggests several di¡erent possibilities including
activation by thrombospondin-1, reactive oxygen species, and
integrin avb6 (Lawrence, 2001). Protease and cell^cell interac-
tions appear to be important. TGF-b1 LAP can neutralize the
epithelial growth inhibitory activity in vitro of all three isoforms
Figure 4. (A) LAP has no e¡ects on cutaneous in£ux of immune
cells in Scl GVHD and (B) LAP does not a¡ect the activation status
of cutaneous immune cells in Scl GVHD. (A) Immune cell in£ux into
skin is not a¡ected by LAP at day 21, when skin thickening is abrogated in
Scl GVHD animals. Flow cytometric analysis was used to quantify subsets
of immune cells in skin single-cell suspensions (see Materials and Meth-
ods) in Scl GVHD with or without LAP treatment, compared to syngeneic
BMTcontrol animals. The percentage of total cutaneous cells that are posi-
tive for each immune cell type are graphed (n¼ 3). As shown previously
(Zhang et al, 2002), monocyte/macrophages are the predominant immune
cells in skin in Scl GVHD. (B) LAP prevents skin ¢brosis in Scl GVHD
but does not a¡ect upregulation of immune cell surface I-A, a marker of
activation, on monocyte/macrophages (CD11bþ ) or T cells (CD3þ )
(n¼ 3).
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of TGF-b, with the e¡ective dosages for 50% neutralization
(ED50) of TGF-b activity 58-fold molar excess for TGF-b1 com-
pared to the other isoforms (Bottinger et al, 1996). The e¡ects of
TGF-b1 LAP on in vivo ¢brosis are not well understood,
although studies in other animal models demonstrate its e⁄cacy
in blocking liver ¢brosis (Bottinger et al, 1996). The e¡ects of
exogenous LAP on homeostasis of matrix-bound LTGF-b1,
soluble LTGF-b, and mature active TGF-b1 in vivo are not
known. In summary, Abs to TGF-b inhibit TGF-b functions,
speci¢cally chemoattraction, collagen synthesis, and activation of
immune cells, whereas the e¡ects of LAP on chemoattraction, on
immune cell in£ux into skin, and on immune cell activation are
not known. In our model, LAP appears to a¡ect these parameters
quite di¡erently than Abs toTGF-b.
CTGF in Scl GVHD CTGF plays an important role in
the development and maintenance of ¢brosis but not in the
initiation of ¢brosis because CTGF alone does not mimic the
e¡ects of TGF-b on ¢broblasts in culture (Kothapalli et al, 1997).
Many pro¢brogenic activities of TGF-b may be mediated via
CTGF, which is thought to act downstream from TGF-b. By
quantitative real-time PCR analysis, cutaneous CTGF mRNA
expression is upregulated in Scl GVHD mice by day 21 after
BMT, along with TGF-b1 mRNA. LAP treatment blocks the
upregulation of both cutaneous TGF-b1 and CTGF mRNAs
followed by reduced type I collagen protein and decreased skin
thickening. These results are consistent with other published
data showing that anti-TGF-b Abs block the increased synthesis
of CTGF protein in cultured rat renal mesangial cells (Riser et al,
2000). CTGF expression may be mediated by TGF-b-dependent
pathways with a highly selective response to TGF-b at the
transcriptional level. Therefore, both TGF-b and CTGF appear
to play a role in ¢brosis in Scl GVHD and both are a¡ected by
in vivo LAP administration.
E¡ects of LAP in early Scl GVHD The di¡erent e¡ects of
anti-TGF-b Abs and peptide LAP are intriguing, but we do not
have a ¢nal answer on how these two inhibitors of TGF-b act
in vivo. The cutaneous TGF-b environment is a complex one,
with multiple forms of TGF-b (soluble LTGF-b, soluble active
Figure 5. Model for LAP treatment in murine Scl GVHD (A) and model for inhibition of TGF-b by blocking Abs toTGF-b or by LAP (B).
(A) TGF-b is secreted by monocyte/macrophages,T cells, and endothelial cells and released by platelets as latent TGF-b (LTGF-b), which consists of TGF-b
and the inhibitor of TGF-b, latency-associated peptide (LAP). The soluble form of LTGF-b1 is shown.The matrix-bound form is not shown.We hypothe-
sized that by injecting recombinant human LAP for TGF-b1 in vivo, we could inhibit skin thickening in mice with Scl GVHD by binding up the free
mature active TGF-b. (B) TGF-b1 secreted by tissue monocyte/macrophages and T cells has pleiotropic e¡ects, not only on cutaneous collagen synthesis,
but also on chemokine synthesis and recruitment of immune cells to skin. Abs toTGF-b may therefore interfere with ¢brosis at multiple steps. LAP, on the
other hand, may act more speci¢cally by directly inhibiting TGF-b protein. In our experiments, it also appears to a¡ect synthesis of TGF-b1 mRNA in
skin. There also appears to be a feedback loop of LAP in synthesis of TGF-b and CTGF mRNAs.
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TGF-b, matrix-bound LTGF-b).We hypothesize that in early Scl
GVHD, activation of LTGF-b may generate an autocrine loop of
secretion of endogenous TGF-b that accumulates on the surface
of cells (mainly ¢broblasts, monocyte/macrophages, T cells) and
in extracellular matrix. Downstream CTGF is upregulated in
response to the elevation of TGF-b, therefore initiating another
autocrine loop of CTGF synthesis. CTGF then orchestrates with
active TGF-b, promoting collagen synthesis and deposition in
skin. LAP may prevent skin ¢brosis by binding to active TGF-b
and disrupting production of bothTGF-b and CTGF. Previously
synthesized TGF-b protein bound to matrix in tissue could still
function as a chemoattractant. Thus LAP may not a¡ect immune
cell in£ux or activation in skin.
In summary, in murine Scl GVHD, LAP treatment inhibits the
upregulation of TGF-b1 and CTGF mRNAs and collagen
protein synthesis, thereby preventing skin ¢brosis. LAP may be
a useful new therapy for Scl GVHD, scleroderma, and other
TGF-b-driven ¢brosing diseases because it prevents skin thicken-
ing without a¡ecting immune cell in£ux or activation. Murine
Scl GVHD is a valuable model to further investigate these path-
ways in vivo and to better understand the roles of TGF-b1 and
LAP. It also provides a unique system in which to design novel
interventions for ¢brosing diseases including scleroderma and
human Scl GVHD.
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